Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30679394 | 1.00 | IRAK4 (0.37) | IRAK4AURKAMAP3K7FLT3SYK | |
| SCHEMBL21371622 | 0.78 | IRAK4 (0.37) | IRAK4AURKAMAP3K7FLT3SYK | |
| SCHEMBL4302108 | 0.77 | IRAK4 (0.39) | IRAK4AURKAMAP3K7FLT3SYK | |
| SCHEMBL360516 | 0.77 | IRAK4 (0.39) | IRAK4AURKAMAP3K7FLT3SYK | |
| SCHEMBL29936180 | 0.77 | IRAK4 (0.39) | IRAK4AURKAMAP3K7FLT3SYK | |
| SCHEMBL20594478 | 0.76 | IRAK4 (0.34) | IRAK4 | |
| SCHEMBL24375572 | 0.72 | IRAK4 (0.39) | IRAK4AURKAMAP3K7FLT3SYK | |
| SCHEMBL22430212 | 0.72 | IRAK4 (0.36) | IRAK4AURKAMAP3K7FLT3SYK | |
| SCHEMBL12162964 | 0.72 | IRAK4 (0.34) | IRAK4 | |
| SCHEMBL15067257 | 0.72 | CYP2A6 (0.40) | IRAK4AURKAMAP3K7FLT3SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190855-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2024-06-13 | — | — | US | disclosed |
| EP-4291176-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| WO-2015076600-A1 | NOVEL LIGHT EMISSION COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | 주식회사 동진쎄미켐 | 2015-05-28 | — | — | WO | disclosed |
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | IRAK4 63/4885AURKA 129/4885MAP3K7 5/4885 |
| US-20240190855-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | CDK3, CDK8, CDK6 | IRAK4 2357/4885AURKA 172/4885MAP3K7 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.